Theradiag: Signing of a Distribution Agreement with BIOSYNEX of Their AMPLIQUICK SARS-CoV-2 PCR Test
13 Gennaio 2022 - 7:30AM
Business Wire
Regulatory News:
THERADIAG (ISIN : FR0004197747, Mnémonique : ALTER), a
company specializing in in vitro diagnostics of autoimmune diseases
and theranostics, and BIOSYNEX (ISIN : FR0011005933, Mnémonique
: ALBIO), leader on the Rapid Diagnostic Test market in France,
announce the signing of a distribution agreement.
Following acquisition of shares on the market and its
participation in THERADIAG's rights issue in November 20211,
BIOSYNEX held 2,468,932 shares on November 29, 2021, representing
18.82% of THERADIAG's capital2.
Within this context, constructive discussions have taken place
between the management of BIOSYNEX and THERADIAG with the aim of
identifying areas of cooperation and performance improvement and
implementing specific action plans.
In this respect, an initial two-year distribution agreement was
signed between THERADIAG and BIOSYNEX for the AMPLIQUICK SARS-CoV-2
PCR test from BIOSYNEX, which will be promoted in hospitals by
THERADIAG, which benefits from a strong presence in hospitals, and
in particular in the vast majority of University Hospitals.
As an extension of this first contract, BIOSYNEX and THERADIAG
intend to explore the possibilities of developing joint
projects.
In addition, it is already envisaged that the Board of Directors
of THERADIAG will include a representative of BIOSYNEX whose
appointment will be submitted to the vote of the shareholders at
the latest at the next THERADIAG General Meeting.
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
https://www.theradiag.com/
About Biosynex
Founded in 2005 and based in Illkirch-Graffenstaden in Alsace, a
major player in public health with more than 200 employees, the
French laboratory Biosynex designs, manufactures and distributes
Rapid Diagnostic Tests (RDTs). In their professional version, they
offer better medical care for patients thanks to the speed of their
result and their simplicity of use. In their self-test version,
they allow patients to self-monitoring various pathologies thus
ensuring better prevention and accelerating the demand for care.
Biosynex is the leader in the RDT market in France and is the only
player to fully control its value chain thanks to its technology
platform, which can be used in a variety of applications and is
adapted to different types of users such as laboratories,
hospitals, doctors and the general public. More information on
www.biosynex.com
_________________________ 1 THERADIAG press release of November
24, 2021 2 BIOSYNEX press release of November 29, 2021.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220112005904/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Biosynex Larry Abensur Président directeur-général
investisseurs@biosynex.com
EuroLand Corporate Julia Bridger Listing Sponsor +33 1 44
70 20 84 jbridger@elcorp.com
CapValue Gilles Broquelet Communication financière + 33 1
80 81 50 00 gbroquelet@capvalue.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024